About: Physiology-guided revascularization versus optimal medical therapy of non-culprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial()

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Physiology-guided revascularization versus optimal medical therapy of non-culprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial() Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Physiology-guided revascularization versus optimal medical therapy of non-culprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial()
Creator	Luis, José Campo, Gianluca Dudek, Dariusz Varbella, Ferdinando Barbato, Emanuele Biscaglia, Simone Colaiori, Iginio Colombo, Antonio Escaned, Javier Fernandez-Aviles, Francisco Fileti, Luca Giannini, Francesco Guiducci, Vincenzo Ibañes, Enrique Lanzilotti, Valerio Maietti, Elisa Menozzi, Mila Moreno, Raul Redondo, Alfredo Ruozzi, Marco Santarelli, Andrea Santos, Ignacio Tebaldi, Matteo Zoccai, Giuseppe Gil, Díez
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Myocardial infarction (MI) in elderly patients is associated with unfavorable prognosis, and it is becoming an increasingly prevalent condition. The prognosis of elderly patients is equally impaired in ST-segment elevation (STE) or non-STE (NSTE), and it is markedly worsened by the common presence of multivessel disease (MVD). Given the limited evidence available for elderly patients, it has not yet been established whether, as for younger patients, a complete revascularization strategy in MI patients with MVD should be advocated. We present the design of a dedicated study that will address this research gap. METHODS AND DESIGN: The FIRE trial is a prospective, randomized, international, multicenter, open-label study with blinded adjudicated evaluation of outcomes. Patients aged 75 years and older, with MI (either STE or NSTE), MVD at coronary artery angiography and a clear culprit lesion will be randomized to culprit-only treatment or to physiology-guided complete revascularization. The primary endpoint will be the patient-oriented composite endpoint (POCE) of all cause death, any MI, any stroke, any revascularization at one year. The key secondary endpoint will be the composite of cardiovascular death and MI. Quality of life and physical performance will be evaluated as well. All components of the primary and key secondary outcome will be tested also at 3 and 5 years. The sample size for the study is 1400 patients. IMPLICATIONS: The FIRE trial will provide evidence on whether a specific revascularization strategy should be applied to elderly patients presenting MI and MVD in order to improve their clinical outcomes.
has issue date	2020-08-18(xsd:dateTime)
bibo:doi	10.1016/j.ahj.2020.08.007
bibo:pmid	32822656
has license	no-cc
sha1sum (hex)	107837a44b8db037d5999edad80362f21d1a4155
schema:url	https://doi.org/10.1016/j.ahj.2020.08.007
resource representing a document's title	Physiology-guided revascularization versus optimal medical therapy of non-culprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial()
has PubMed Central identifier	PMC7434365
has PubMed identifier	32822656
schema:publication	Am Heart J
resource representing a document's body	covid:107837a44b8db037d5999edad80362f21d1a4155#body_text
is schema:about of	named entity 'infarction' named entity 'revascularization' named entity 'WORD' named entity 'ARTICLE' named entity 'BACKGROUND' named entity 'HTTPS' named entity 'COUNT' named entity 'MEDICAL THERAPY' named entity 'TRIAL' named entity 'LESIONS' named entity 'N A' named entity 'ABSTRACT' named entity 'CITE' named entity 'patients' named entity 'American Heart Journal' named entity 'optimal medical therapy' named entity 'revascularization' named entity 'Physiology' named entity 'optimal medical therapy' named entity 'myocardial infarction' named entity 'SAQ' named entity 'angina' named entity 'MVD' named entity 'prognosis' named entity 'EQ-5D' named entity 'clinical endpoint' named entity 'revascularization' named entity 'MVD' named entity 'clinical presentation' named entity 'angiographic' named entity 'RCTs' named entity 'primary endpoint' named entity 'elderly patients' named entity 'Elderly Patients' named entity 'Revascularization' named entity 'NSTEMI' named entity 'co-morbidity' named entity 'infrared spectroscopy' named entity 'nitrates' named entity 'NSTEMI' named entity 'quality of life' named entity 'American Heart Association' named entity 'STEMI' named entity 'ischemia' named entity 'revascularization' named entity 'error control' named entity 'bleedings' named entity 'revascularization' named entity 'lesion' named entity 'lesion' named entity 'revascularization' named entity 'DAPT' named entity 'lesion' named entity 'Epidemiology' named entity 'stroke' named entity 'Myocardial Infarction' named entity 'STATA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software